CELZ — Creative Medical Technology Hol

Is CELZ overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

Creative Medical Technology Hol (CELZ) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $1.08. The rating moved from Neutral to Oversold on August 18, 2026.

See all oversold Healthcare stocks →

AI analysis

Creative Medical Technology Hol (CELZ) is a micro‑cap healthcare issuer with limited publicly available financial detail in the provided dataset. The equity exhibits typical small‑cap risks: thin liquidity, potential for heavy dilution, and high sensitivity to discrete news or financing events. Sector momentum toward growth healthcare names could intermittently support the share price, but lack of transparent filings and unclear cash runway make near‑term prospects highly uncertain. Primary drivers to watch are any corporate announcements (partnerships, licensing, clinical/regulatory updates), financing terms if capital is raised, and improvements in disclosure/transparency. Given the information gaps, outcomes range from short‑term spikes on positive news to material downside from dilution, regulatory issues, or market risk‑off episodes.

Key factors

  • Limited publicly available financial reporting and no recent EDGAR comparables in the provided dataset, reducing visibility into revenue, cash flow, and liabilities
  • Typical micro‑cap / OTC characteristics: low liquidity, wide bid/ask spreads, and price sensitivity to news and financing events
  • Potential catalysts exist (corporate announcements, licensing/partnerships, clinical or regulatory updates) that could meaningfully move the stock on limited new information
  • Macro/sector tone is cautiously optimistic for growth-oriented healthcare names, which can provide intermittent risk‑on flows into small health/biotech names
  • High execution dependence on capital raises or transactional activity to fund operations and any commercialization effort

Risks

  • Severe dilution risk from equity financings if cash runway is constrained
  • Regulatory or product development setbacks that materially reduce prospective revenue opportunities
  • Very low trading volume and investor attention can amplify volatility and impair orderly exits for shareholders
  • Lack of transparent, timely financial disclosures increases information asymmetry for investors
  • Competition from better‑capitalized incumbents or alternative technologies
  • Macro shocks (rates, risk‑off sentiment) and sector rotation away from small healthcare names could cause sharp price declines

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CELZ — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.